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The Lymnaea Cardioexcitatory Peptide (LyCEP) Receptor: A
G-Protein–Coupled Receptor for a Novel Member of the RFamide
Neuropeptide Family
Cornelis P. Tensen,1,2 Kingsley J. A. Cox,3 August B. Smit,2 Roel C. van der Schors,2 Wolfgang Meyerhof,4
Dietmar Richter,4 Rudi J. Planta,1 Petra M. Hermann,2 Jan van Minnen,2 Wijnand P. M. Geraerts,2
Jaco C. Knol,1 Julian F. Burke,3 Erno Vreugdenhil,1 and Harm van Heerikhuizen1
Departments of 1Biochemistry and Molecular Biology and 2Molecular Neurobiology, Research Institute Neurosciences,
Vrije Universiteit, 1081 HV Amsterdam, The Netherlands, 3Sussex Neuroscience Research Centre, School of Biological
Sciences, University of Sussex, Falmer, Brighton BN1 9QG, United Kingdom, and 4Institut für Zellbiochemie und Klinische
Neurobiologie, Universitäts-Krankenhaus Eppendorf, 20246 Hamburg, Germany
A novel G-protein–coupled receptor (GRL106) resembling neu-
ropeptide Y and tachykinin receptors was cloned from the
mollusc Lymnaea stagnalis. Application of a peptide extract
from the Lymnaea brain to Xenopus oocytes expressing
GRL106 activated a calcium-dependent chloride channel. Us-
ing this response as a bioassay, we purified the ligand for
GRL106, Lymnaea cardioexcitatory peptide (LyCEP), an
RFamide-type decapeptide (TPHWRPQGRF-NH2) displaying
significant similarity to the Achatina cardioexcitatory peptide
(ACEP-1) as well as to the recently identified family of mamma-
lian prolactin-releasing peptides. In the Lymnaea brain, the cells
that produce egg-laying hormone are the predominant site of
GRL106 gene expression and appear to be innervated by
LyCEP-containing fibers. Indeed, LyCEP application transiently
hyperpolarizes isolated egg-laying hormone cells. In the Lym-
naea pericardium, LyCEP-containing fibers end blindly at the
pericardial lumen, and the heart is stimulated by LyCEP in vitro.
These data confirm that LyCEP is an RFamide ligand for
GRL106.
Key words: neuropeptide receptor; mollusc; HPLC; Xenopus
oocyte; RFamide; orphan receptor
Neuropeptides form a structurally diverse class of signaling mol-
ecules. Despite their diversity, various families with specific se-
quence characteristics can be discerned. For instance, many
members end in the sequence RFamide. Among these are g1-
MSH, the anti-opioids F-8-Famide (NPFF) and A-18-Famide in
vertebrates, and FMRFamide and FMRFamide-related peptides
in invertebrates (Yang et al., 1985; Greenberg et al., 1988). These
examples represent only a limited selection from a range of
naturally occurring RFamides. These peptides display a wide
range of peripheral and central actions. To further our under-
standing of the action of RFamide peptides, it is necessary to
study the intracellular signaling pathways that are triggered by
these molecules, beginning with the peptide receptors involved.
In Lymnaea stagnalis, a number of RFamide neuropeptides
have been characterized, including FMRFamide, FLRFamide,
GDPFLRFamide, and SDPFLRFamide (Ebberink et al., 1987;
Saunders et al., 1991, 1992). FMRFamide was originally identified
by its cardioexcitatory actions (Price and Greenberg, 1977), but
this peptide also modulates neuronal activities (e.g., Cottrell et
al., 1984). As such L. stagnalis represents an attractive animal
model in which to study RFamide peptide signaling. In the search
for an FMRFamide receptor, an FMRFamide-gated sodium
channel was characterized in neurons of the snail Helix aspersa
(Lingueglia et al., 1995). Despite the clear effects of FMRFamide
on the snail heart, this FMRFamide-gated channel appeared to be
absent from this tissue. Moreover, evidence exists that FMRF-
amide can also activate a G-protein–coupled receptor (GPCR)
(Brezina et al., 1987; Volterra and Siegelbaum, 1988). This re-
ceptor has not been identified yet, but it would be very interesting
to know its molecular details to develop molecular tools to study
its role in FMRFamide signaling.
In the past, we have cloned several GPCRs from the CNS of L.
stagnalis, but none of these seems to represent a receptor for an
RFamide-type neuropeptide (Tensen et al., 1994a,b; Cox et al.,
1997). Here, we report the characterization of a novel GPCR that
is expressed in the heart and brain of L. stagnalis as well as the
identification of its ligand, designated Lymnaea cardioexcitatory
peptide (LyCEP). The latter appears to be an RFamide that is
akin to cardioactive peptides from the evolutionary distant snails
Achatina fulica and Aplysia californica. Moreover, we have found
that the LyCEP receptor is expressed in a group of defined
egg-laying hormone–producing neurons that are well suited for
studying intracellular signaling by LyCEP at the single-cell level.
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MATERIALS AND METHODS
Isolation of a cDNA clone encoding GRL106. Total RNA isolated from
Lymnaea hearts was converted into cDNA by the use of oligo-dT and
reverse transcriptase as described previously (Tensen et al., 1994a). Two
degenerate primers were synthesized on the basis of conserved amino
acid sequences within transmembrane regions III and VI of G-protein–
coupled neuropeptide receptors (Probst, 1992). The sense primer was
59-CCGGATCCG(CT)(GC)AT(CT)(GA)(GC)(GC)IT(GT)GAC(CA)-
G(GC)TA-39; the antisense primer was 59-ACGAATTCGG(GC)(CA)-
ICCA(GA)CAGAI(GC)(GA)(CT)(GA)AA-39 (BamHI and EcoRI re-
striction sites in italics). These primers were used in a PCR with heart
cDNA using the conditions described earlier (Tensen et al., 1994a), and
PCR products of the expected size (400–800 bp) were isolated, cloned,
and sequenced (Sambrook et al., 1989). The nucleotide sequence of a
PCR product putatively encoding part of a novel GPCR was used to
design specific oligonucleotides. The latter were used to isolate the
corresponding full-length clone from a Lymnaea CNS cDNA library in
lZAP II, using a PCR-based screening strategy (Bloem and Yu, 1990;
Gibbons et al., 1991). The cDNA insert was excised in vivo as a pBlue-
script SK(2) phagemid (designated pBS GRL106) and was sequenced
from both strands using the chain termination method (Sanger et al.,
1977).
Isolation of a cDNA clone encoding preproLyCEP. A degenerate primer
was synthesized, based on the amino acid sequence of LyCEP. This
primer was 59-CCAAGCTTAC(GATC)CC(GATC)CA(TC)TGG(AC)-
G(GATC)CC(GATC)CA(AG)GG-39. The oligonucleotide was provided
with a HindIII restriction site (in italics) at its 59 end and was used as a
primer in a PCR, with cDNA isolated from a lZAP II cDNA library of
the Lymnaea CNS as template. As reverse primer, an oligonucleotide was
used complementary to a pBluescript sequence. cDNA was amplified by
the use of these two primers for 40 cycles: 94°C for 20 sec, 58°C for 20 sec,
and 72°C for 1 min. Amplified cDNA was cloned in M13 after digestion
with HindIII and EcoRI, sequenced, and used to screen a cDNA library.
We screened 20,000 clones of an amplified library of the CNS of L.
stagnalis in lZAP II, using charged Nylon filters (Boehringer Mannheim,
Mannheim, Germany) at a density of 1000 pfu/20 cm 2 filter. Clones were
purified by rescreening at a lower plaque density. Hybridization was
performed in 63 SSC (13 SSC, 0.15 M NaCl and 0.015 M sodium citrate)
for 16 hr at 65°C. Membranes were washed in 13 SSC for 45 min at 65°C
and autoradiographed.
Oocyte expression of GRL106 and electrophysiolog ical recordings. The
full open reading frame of GRL106 was amplified by 25 cycles of PCR
using 100 ng of pBS GRL106 as a template, two specific oligonucleotide
primers, and Ultma DNA polymerase under conditions recommended by
the manufacturer (Perkin-Elmer, Norwalk, CT). The sense primer was
59-GTTAAGCTTCCACCATGGCGATGGCGAACAGCGA-39; the an-
tisense primer was 59-CATTCTAGATATCAAAGATACATATCG-
TTTGACAC-39 (HindIII and XbaI restriction sites in italics). The re-
sultant cDNA was cloned as a HindIII–XbaI fragment into the oocyte
expression vector pGEMHE (Liman et al., 1992). The nucleotide se-
quence of the resultant construct was verified to check for any PCR-
generated errors, and the plasmid was used as a template in a PCR with
primers flanking the T7 and Sp6 RNA polymerase promoters. The PCR
product was gel-purified and used as a template for the synthesis of
capped sense cRNA with T7 RNA polymerase in the presence of 2 mM
m 7G(59)ppp(59)G according to the manufacturer’s instructions (New
England Biolabs, Beverly, MA). The cRNA was diluted with double-
distilled water to 10 ng/ml, and 50 nl was injected into manually defol-
liculated Xenopus laevis oocytes. After 2–3 d, whole-cell current mea-
surements were performed as described previously (Meyerhof et al.,
1988).
Crude peptide extract f rom Lymnaea brains. Samples of Lymnaea CNS
were dissected, collected on dry ice, and stored at 260°C until use. The
nervous systems were rapidly thawed at room temperature, sonicated in
1 M acetic acid on ice, and centrifuged at 10,000 3 g for 5 min at 4°C, and
the resulting supernatant was applied to a C18 solid phase extraction
column (Supelclean from Supelco). Bound material was eluted with 60%
acetonitrile and 7 mM trifluoroacetic acid (TFA), lyophilized, and dis-
solved in double-distilled water.
Purification of LyCEP. The crude peptide mixture was size-
fractionated by high-performance gel permeation chromatography
(HPGPC) on Protein-Pak columns I-125 and I-300 connected in series
(Waters Associates, Milford, MA) with 7 mM TFA in 30% acetonitrile as
a running buffer and 1 ml fractions collected at a flow rate of 1 ml/min.
Fractions were lyophilized, redissolved in double-distilled water, and
tested in the Xenopus oocyte assay. The bioactive fraction was then
subjected to reversed-phase HPLC (rpHPLC) on a Nucleosil C18 column
(Hichrom; 250 3 4.6 mm) by the application of linear gradients of
acetonitrile in 7.5 mM TFA (0% acetonitrile for 10 min; then from 0 to
60% acetonitrile over 60 min). Fractions of 300 ml were collected at a
flow rate of 300 ml /min. The active fraction was lyophilized, taken up in
double-distilled water, and rechromatographed on a similar column
(Nucleosil C18; 250 3 2.1 mm) by the application of linear gradients of
acetonitrile in 0.05% HCl (from 0 to 10% acetonitrile in 10 min, then
from 10 to 25% acetonitrile over 60 min, and finally to 60% acetonitrile
in 10 min). At this stage, the bioactive fraction appeared to contain a
single protein peak as assessed spectroscopically. It was lyophilized, and
the solute was redissolved in double-distilled water.
Amino acid sequence determination, peptide synthesis, and mass deter-
mination. Amino acid sequences were determined with an automated
sequencer (model 477; Applied Biosystems, Foster City, CA) and an
on-line rpHPLC system (model 120A; Applied Biosystems) to detect
phenylthiohydantoin amino acids using sequencing programs recom-
mended by the manufacturer.
LyCEP was chemically synthesized on an Applied Biosystems 432A
peptide synthesizer according to the manufacturer’s instructions and was
HPLC-purified. The precise molecular masses of natural and synthetic
LyCEP were obtained using a Quattro-BQ triple quadrupole mass spec-
trometer (Fisons). The mass spectrometer was equipped with an electron
spray atmospheric pressure ionization source. The peptide was dissolved
in 20 ml of 50% acetonitrile/1% formic acid, and the resultant solution
was injected via a 10 ml loop into the electron spray source. The flow rate
was 4 ml /min; the mobile phase was 50% acetonitrile/1% formic acid.
Data were collected over a suitable mass range, and several 10 sec
continuum scans were accumulated.
Immunohistochemistry and in situ hybridization. Dissected CNS of L.
stagnalis was frozen in Freon cooled by liquid nitrogen, lyophilized in a
tissue freeze dryer, and then fixed in paraformaldehyde vapor (80°C for
1 hr) and embedded in paraffin. Sections of 7 mm were mounted on
chromalum- and gelatin-coated slides and dried overnight at 37°C. For
some experiments alternate sections were mounted on different slides to
be able to compare the various antibody stainings as well as the immu-
nohistochemistry and in situ hybridization results.
For immunohistochemical detection of LyCEP, a polyclonal Achatina
cardioexcitatory peptide (ACEP-1) antiserum (a gift from Dr. M. Koba-
yashi, Hiroshima, Japan) was used. This antiserum was first tested for its
ability to recognize synthetic LyCEP and for the absence of cross-
reactivity with nonrelated RFamide peptides in dot blot assays. Sections
were incubated overnight with anti-ACEP-1 at a 1:500 dilution in PBS
plus 0.5% Triton X-100 (PBST) with 0.2% gelatin, washed with PBST,
and incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG
(1:100 dilution; DAKO, Glostrup, Denmark). After three final rinses in
PBST, phosphatase activity was detected with 0.03% nitroblue tetrazo-
lium (NBT; Boehringer Mannheim), bromochloroindolyl phosphate
(BCIP; Boehringer Mannheim), and diaminobenzidine tetrahydrochlo-
ride (Sigma, St. Louis, MO) in PBST containing 0.015% H2O2. Egg-
laying inducing hormone (ELH) was detected using a monoclonal anti-
ELH antibody (1:3000 dilution). In this case a peroxidase-conjugated
rabbit anti-mouse secondary antibody (1:100 dilution; DAKO) was used;
peroxidase activity was detected with 0.03% diaminobenzidine tetrahy-
drochloride (Sigma) in PBST containing 0.015% H2O2.
For double immunohistochemical stainings, sections were incubated
simultaneously with the ACEP-1 and ELH antibodies (1:500 and 1:3000,
respectively). Next, the ACEP-1 antibody was detected as detailed above.
After thorough rinsing in PBST plus 0.2% gelatin, sections were prein-
cubated with 10% normal rabbit serum, and subsequently the ELH
antibody was detected as described.
For in situ hybridization, pBS106 was used as a template to generate a
PCR product with primers flanking the T7 and T3 RNA polymerase
promoters. The linear fragment was gel-purified and used as a template
for the synthesis of antisense cRNA in the presence of digoxigenin-
labeled UTP according to the manufacturer’s instructions (Boehringer
Mannheim). In a similar manner, sense cRNA was synthesized as a
negative control. Sections of the CNS of L. stagnalis were pretreated with
0.2% pepsin in 0.2 M HCl for 20 min at 37°C, rinsed with double-distilled
water, and subsequently hybridized using 80 ml of hybridization buffer
(per slide) containing 2–5 ng of cRNA per ml. Hybridization conditions,
treatments after hybridization, as well as the detection of hybrids with an
alkaline phosphatase-conjugated sheep anti-digoxigenin antibody were as
described (Tensen et al., 1994a).
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Effects of LyCEP on the Lymnaea heart. The auricle of the heart was
dissected and attached to a displacement transducer in a 1 ml chamber
filled with snail Ringer’s solution (Geraerts et al., 1984). LyCEP was
added under continuous superfusion with Ringer’s solution at a flow rate
of 1 ml/min, and contractions were recorded on paper. Responses of the
auricle were quantified 2.5 min after addition of the peptide for a period
of 2 min as described previously (Geraerts et al., 1984)
Effects of LyCEP on caudodorsal cells. Caudodorsal cells (CDCs;
ELH–producing cells) were isolated from the CNS under aseptic condi-
tions [for a detailed procedure, see Ridgway et al. (1991)]. The nervous
systems were incubated for 20–25 min in Leibovitz L-15 defined medium
(DM; special order; Life Technologies, Gaithersburg, MD) with 0.67
mg/ml trypsin (type III; Sigma) at room temperature (20–22°C). After
enzyme treatment, the brains were rinsed for 10–15 min in DM contain-
ing 0.67 mg/ml soybean trypsin inhibitor (type I-S, Sigma). Isolated cells
were plated on poly-L-lysine (Sigma)-coated 35 mm diameter Petri dishes
(Falcon) filled with DM or brain-conditioned DM (CM) (see Ridgway et
al., 1991). Intracellular recordings of the isolated CDCs were made
24–30 hr after plating. The cells were impaled with glass microelectrodes
(TW150 F-6; WPI; resistance, 50–60 MV) filled with 0.5 M potassium
acetate and 0.01 M potassium chloride. The recording chamber was
continuously superfused with DM or standard saline. LyCEP (5–10 mM)
or a control solution was applied close to the somata. The concentrations
used were based on the concentration of FMRFamide that resulted in a
saturated response in isolated CDCs (see Brussaard et al., 1988). Fast
green (10 mM; Sigma) was also added to monitor application of the drugs
and control solutions visually.
RESULTS
Molecular cloning of a novel G-protein–coupled
neuropeptide receptor from L. stagnalis
On the basis of two amino acid sequence motifs that are highly
conserved among many G-protein–coupled neuropeptide recep-
tors, degenerate oligonucleotide primers were designed (see Ma-
terials and Methods) and used in a PCR with cDNA prepared
from Lymnaea heart RNA. As revealed by nucleotide sequence
analysis, one of the PCR products obtained encoded part of a
novel putative GPCR. Based on this nucleotide sequence, an
oligonucleotide was designed to screen cDNA libraries using a
PCR-based strategy (Bloem and Yu, 1990; Gibbons et al., 1991).
From a CNS library, a 1.5 kb cDNA designated GRL106 was
isolated and sequenced (the nucleotide sequence for GRL106 has
been deposited into GenBank and is available under accession
number AF037444).
In the GRL106 cDNA sequence, an A/T-rich untranslated
region of 66 nucleotides precedes a 1395 nucleotide open reading
frame that contains an initiation codon obeying the Kozak con-
sensus (Kozak, 1989). Hydrophobicity analysis of the predicted
protein product of 465 amino acids suggests the presence of seven
membrane-spanning segments (Fig. 1), which is typical of
GPCRs. Another feature of GPCRs is a putative disulfide bridge
between extracellular loops I and II. Residues Cys 171 and Cys247
may form such a bond in GRL106. Furthermore, as in all GPCRs,
there are consensus sites for N-linked glycosylation within the
predicted extracellular N terminal of GRL106, as well as sites for
phosphorylation of serine and threonine residues within putative
intracellular loops II and III and in the C terminal. In addition,
the receptor protein harbors a typical B-B-X-X-B motif (in which
B is a basic residue and X is any nonbasic residue) at the
C-terminal part of the third intracellular loop. Such a conserved
motif is found in many G-protein–coupled receptors and has
been implicated in G-protein activation (Okamoto and Nishi-
moto, 1992). Database searches indicate that GRL106 shares the
highest amino acid sequence similarity (;40%) with invertebrate
G-protein–coupled neuropeptide receptors such as the Drosoph-
ila NPY receptor (Li et al., 1992), the Drosophila and Stomoxys
calcitrans tachykinin(-like) receptors (Li et al., 1991) (accession
number U52347), and vertebrate tachykinin receptors (Shige-
moto et al., 1990; Takeda et al., 1991). Similarity is highest in the
transmembrane domains, especially in domain VII (50% identity
between all receptors).
Identification of a neuropeptide ligand for GRL106 in
Lymnaea brain extracts
Various GPCRs, including the vertebrate NPY and tachykinin
receptors (Shigemoto et al., 1990; Li et al., 1991), trigger intra-
cellular calcium mobilization after ligand binding. Because of the
resemblance of GRL106 to the latter receptors, we hypothesized
that it would be possible to screen for a GRL106 ligand by
measuring the intracellular calcium mobilization. To do so, we
made use of Xenopus oocytes, a well-established model system for
expression and functional analysis of GPCRs, in which receptor-
generated calcium signals can be detected easily via voltage-clamp
analysis of an endogenous calcium-dependent chloride channel
(Meyerhof et al., 1988). This system has been used for the ex-
pression and analysis of numerous G-protein–coupled receptors
cloned from vertebrates [e.g., tachykinin receptors (Shigemoto et
al., 1990)] and invertebrates [e.g., conopressin receptors (van
Kesteren et al., 1995, 1996)]. Indeed, when oocytes were injected
with GRL106-encoding cRNA and were subsequently challenged
with a crude peptide extract from the Lymnaea brain, a dose-
dependent inward chloride current was observed (Fig. 2A). This
response was not seen in oocytes injected with cRNA lacking
GRL106-encoding sequences (data not shown).
To purify the GRL106-activating molecule(s), we size-
fractionated the peptide extract (Fig. 2B, top) and tested fractions
for their ability to trigger a chloride current in GRL106-
expressing oocytes. Fractions that were active were subjected to
further HPLC fractionation and testing until a single active
fraction remained (Fig. 2B, middle, bottom). As revealed by mass
spectrometry, the final preparation contained two peptides with
molecular masses of 1281 and 1296 Da. However, amino acid
sequence analysis of the two peptides yielded a single sequence of
Figure 1. Deduced amino acid sequence and protein model of GRL106.
Amino acids are given in single letter code. Potential N-linked glycosyla-
tion sites (dots) and putative protein kinase C ( filled circles), casein kinase
2 (squares), and cAMP-dependent protein kinase phosphorylation (dia-
mond) sites are indicated. The nucleotide sequence for GRL106 has been
deposited into GenBank and is available under accession number
AF037444.
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Figure 2. Functional expression of GRL106 in Xenopus oocytes and purification of the GRL106 ligand from Lymnaea brain extracts. A, Whole-cell
current of a Xenopus oocyte expressing GRL106 and responding to a Lymnaea brain peptide extract. GRL106-encoding cRNA was injected into Xenopus
oocytes, and after 48 hr whole-cell currents were measured while challenging the oocytes with a crude peptide extract from the Lymnaea CNS. Different
amounts of the extract were applied for 25 sec (indicated by horizontal bars) and then washed out. One CNS equivalent is equal to an amount of extract
that originates from one CNS. B, Purification of the bioactive peptide(s) from the brain extract. Top, HPGPC fractionation on Protein-Pak columns I-125
and I-300 connected in series (elution times of size markers are indicated). Middle, rpHPLC fractionation of the combined bioactive fractions of the
HPGPC column on a Nucleosil C18 column eluted with 7.5 mM TFA and 0–60% acetonitrile. Bottom, rpHPLC fractionation of the combined bioactive
fractions of the first rpHPLC column on a Nucleosil C18 column eluted with 0.05% HCl and 0–25% acetonitrile. Horizontal bars indicate bioactive
fractions. C, Whole-cell current of a Xenopus oocyte expressing GRL106 and responding to 3 nM synthetic LyCEP. D, Dose–response curve of the effect
of synthetic LyCEP on whole-cell currents in Xenopus oocytes expressing GRL106. LyCEP was applied in different concentrations to oocytes, and the
mean membrane current of four experiments was plotted versus the logarithm of the concentration. Error bars denote SEM.
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which the C-terminal residue could not be determined (TPH-
WRPQGRX). The difference of 146 Da between the molecular
mass calculated for the nine amino acid sequence determined via
sequencing and the mass of the 1281 Da peptide suggests that the
10th C-terminal residue is phenylalanine-NH2. Thus, the
GRL106-activating peptide in extracts from the Lymnaea brain
indeed appeared likely to be an amidated neuropeptide,
TPHWRPQGRF-NH2, that belongs to the RFamide family. The
identical N-terminal sequence and the difference in the molecular
masses of the two peptides could be explained by the presence of
an hydroxyproline in the 1296 Da peptide, as was found for
another member of the RFamide family, the head peptide iso-
lated from Aedes aegypti (Matsumoto et al., 1989) and bradykinin
forms (Sasaguri et al., 1988). However, close inspection of the
sequencing data did not show any indication of hydroxyproline, so
the nature of the observed mass difference remains as yet
unexplained.
To prove further the prediction that the isolated peptide ends
in RFamide, we have cloned the cDNA encoding the LyCEP
precursor using the PCR technique (see Materials and Methods).
This cDNA contains an open reading frame of 285 nucleotides
encoding a 94 amino acid LyCEP precursor protein (Fig. 3A). The
predicted sequence for the mature LyCEP is fully consistent with
our protein sequencing data and continues after the Arg at
position 9 with a Phe residue followed by the sequence Gly-Lys-
Arg, the common signal for processing and subsequent amidation
(Bradbury and Smyth, 1991).
To verify whether LyCEP is the endogenous ligand for the
GRL106 receptor, we made a synthetic form of the purified
peptide and used this form to challenge Xenopus oocytes express-
ing the receptor. The synthetic peptide elicited a response similar
to that of the purified peptide (Fig. 2C) and activated the chloride
current with an EC50 of 8 6 0.4 nM (n 5 4; Fig. 2D). In contrast,
GRL106-expressing oocytes did not respond to FMRFamide,
SDPFLRFamide, or GDPFLRFamide in concentrations up to 10
mM. Also, oocytes expressing other receptors such as the cono-
pressin receptors LSCPR1 and LSCPR2 (van Kesteren et al.,
1995, 1996) did not respond to the peptide.
Because the GRL106 ligand displays a striking similarity to
ACEP-1 of the African giant snail Achatina fulica (Fujimoto et
al., 1990) (Fig. 3B), the Lymnaea peptide was designated LyCEP
(Ly for Lymnaea). LyCEP and ACEP-1 are also similar to the
neuropeptide LUQIN, which has been recently isolated from
Aplysia californica (Aloyz and DesGroseillers, 1995) (Fig. 3B).
ELH–producing neurons in the Lymnaea CNS express
GRL106 and are innervated by LyCEP-containing fibers
Being interested in the function of neuropeptides in interneuro-
nal communication, we sought to identify neurons within the
Lymnaea CNS that express GRL106 and thus are the target of the
LyCEP peptide. In situ hybridization of the snail brain with
GRL106 cRNA as a probe revealed that the cognate mRNA is
expressed predominantly in the egg-laying hormone–producing
CDCs, some 150 peptidergic neurons arranged in two clusters in
the right and left cerebral ganglia of the CNS (Fig. 4A) (Geraerts
et al., 1988). CDCs were unequivocally identified in alternate
sections of the cerebral ganglia by immunostaining with an anti-
body recognizing the ELH produced in these cells (Fig. 4B).
GRL106-specific mRNA was also found in a limited number of
neurons within the cerebral, pleural, parietal, and visceral ganglia
of the CNS, whereas sense probes were negative in all cases (data
not shown).
To assess whether the CDCs are indeed contacted by nerve
endings containing LyCEP, we performed an immunohistochem-
ical double staining of the Lymnaea CNS using the ACEP-1 and
ELH antibodies. With the ACEP-1 antibody, prominent staining
was found in neurons within the pedal ganglia. Immunoreactive
axons were observed throughout the CNS, including the commis-
sure of the cerebral ganglia, where extensive ELH immunoreac-
tivity also occurs (Fig. 4C). In fact, axon ramifications immunopo-
sitive for the ACEP-1 antibody were observed in close apposition
to ELH-immunoreactive fibers (Fig. 4C,D). These findings are in
keeping with the notion that LyCEP is an endogenous ligand for
GRL106.
LyCEP inhibits the activity of CDC neurons
To obtain evidence that LyCEP has an effect on CDCs, we
applied the synthetic peptide to CDC neurons isolated from the
Lymnaea CNS and made intracellular recordings of the mem-
brane potential and activity. After local application of 10 mM
LyCEP, 80% of the isolated CDCs showed a hyperpolarization
within 5 sec after the application (Fig. 5A, top; n 5 16). The effect
lasted several tens of seconds and outlasted the presence of the
Figure 3. Nucleotide sequence of preproLyCEP cDNA, the derived
amino acid sequence, and comparison of LyCEP with related peptides. A,
Nucleotide sequence and conceptual translation of the LyCEP precursor
cDNA. The putative proteolytic processing site (Lys-Arg) is boxed, and
the LyCEP domain is underlined. Nucleotide number is indicated at the
right of each line. The predicted amino acid sequence of preproLyCEP is
numbered (on the right) with the first methionine designated position 1.
The stop codon is indicated by an asterisk. The nucleotide sequence of the
preproLyCEP cDNA has been deposited into GenBank under accession
number AF047683. B, Alignment of LyCEP with ACEP-1 from Achatina
fulica (Fujimoto et al., 1990) and with LUQIN from Aplysia californica
(Aloyz and DesGroseillers, 1995). Amino acids identical in LyCEP and
either of the other peptides are boxed.
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peptide. On average, the membrane potential returned to its
pretreatment value within 45 6 9 sec (mean 6 SEM; n 5 13). The
amplitude of the response decreased when the neuron was hyper-
polarized (data not shown). The application of vehicle did not
affect the membrane potential of isolated CDCs (Fig. 5A, bottom;
n 5 4). Suprathreshold stimulation (0.5–0.8 nA; 100 msec; 3 Hz)
for 20–30 sec induced spontaneous regular spiking activity in
17% of the cells (3 out of 18). Application of LyCEP (5 mM)
resulted in an immediate disruption of the beating activity in all
cells (Fig. 5B, top). The neurons resumed their regular spiking
activity 30–40 sec after application. The application of vehicle
never changed the spiking activity of the cells (Fig. 5B, bottom;
n 5 3). Thus, it seems that LyCEP has a direct inhibitory effect on
the activity of CDC neurons.
Is LyCEP a cardioactive neuropeptide?
Because of the close similarity of LyCEP to ACEP-1 as well as the
fact that we originally amplified the GRL106-encoding DNA
fragment from cDNA synthesized from mRNA isolated from the
heart of Lymnaea, it seems likely that LyCEP could stimulate the
snail heart. In fact, immunohistochemical staining of the Lymnaea
heart with an antiserum raised against ACEP-1 (recognizing
LyCEP but not FMRFamide; data not shown) revealed immu-
nopositive nerve fibers entering the heart (Fig. 6). Ramifications
occur in the pericardium, ending blindly. This would suggest
release of LyCEP into the pericardial lumen.
To assess whether LyCEP indeed has an effect on Lymnaea
heart activity, we applied the synthetic peptide to isolated auricle
preparations. Auricles challenged with 1 mM LyCEP responded
with an increase in spontaneous beat rate (Fig. 7A), an effect that
is dose-dependent having an EC50 of ;200 nM (Fig. 7B). Thus,
LyCEP seems to be a cardioactive peptide in much the same way
as the ACEP-1 peptide of Achatina (Fujimoto et al., 1990).
LyCEP is ;25-fold less active in increasing the beat rate of the
isolated auricle compared with its activity for GRL106 expressed
in Xenopus oocytes. This difference can be explained by differ-
ences in receptor densities or in receptor versus G-protein stoi-
Figure 4. Localization of GRL106 and LyCEP in the Lymnaea CNS. A, GRL106 expression revealed by in situ hybridization of a section of the Lymnaea
CNS with a GRL106-specific probe. Within the cerebral ganglia, one of which is shown here, cells located at the position of CDC neurons hybridize with
the GRL106 probe. B, Identification of CDCs by immunohistochemical staining of a section consecutive to the one in A with an antibody against ELH.
The cells hybridizing with the GRL106 probe in A are clearly identified as CDCs by their strong reaction with the ELH antibody; in the commissure,
immunopositive axon bundles and endings of the CDCs can be seen (arrow). Scale bars: A, B, 80 mm. C, Immunohistochemical double staining of the
Lymnaea CNS with an anti-ACEP-1 antibody (blue reaction product) and an anti-ELH antibody (brown reaction product). Shown is part of the cerebral
commissure, where ELH-positive fibers seem to run to and make contact with fibers that react with the ACEP-1 antibody (arrow). Scale bar, 10 mm. D,
In the neuropil of the cerebral ganglion (CG), axons that are immunoreactive to the ACEP-1 antibody and closely opposing axons containing ELH
(arrows), which may indicate a site of contact between the LyCEP-expressing neurons and the CDCs. CC, Cerebral commissure containing the axon
endings of the CDCs (Ae). Scale bar, 5 mm.
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chiometry, parameters that are known to influence EC50 values
(Kenakin, 1997). Heterologous expression in Xenopus oocytes is
likely to give rise to high numbers of receptor protein, whereas
the receptor density on the Lymnaean heart might be low.
DISCUSSION
The RFamide neuropeptides, carrying the sequence Arg-Phe-
amide at their C terminals, form a large family of signaling
molecules comprising both vertebrate (e.g., g1-MSH) and inver-
tebrate (e.g., FMRFamide) members (Greenberg et al., 1988).
Despite the importance of having a detailed knowledge of cellular
signal transduction by RFamides, molecular data on the receptors
that transduce RFamide-mediated signals are lacking. Only re-
cently was an ionotropic FMRFamide receptor characterized
(Lingueglia et al., 1995). Although previous evidence suggested
the existence of metabotropic RFamide receptors (Brezina et al.,
1987; Volterra and Siegelbaum, 1988), to date no such receptor
has been characterized at the molecular level. Here, we present
the characterization of a novel GPCR from the CNS of the
mollusc Lymnaea stagnalis and the isolation and identification of
its ligand, an RFamide neuropeptide designated LyCEP. We
initially performed PCR on cDNA synthesized from RNA iso-
lated from the heart of Lymnaea, because we reasoned that an
FMRFamide receptor, or a receptor for a related peptide, might
be identified among the GPCRs expressed in this tissue because
of the clear effects of FMRFamide and its congeners on the snail
heart (Buckett et al., 1990a,b). In addition, we expected, com-
pared with the CNS, a less complex mixture of transcripts encod-
ing neuropeptide receptors. Indeed, with a combination of oligo-
nucleotide primers shown previously to be successful for the
amplification of cDNAs encoding GPCRs in the CNS of L.
stagnalis, partial cDNA sequences encoding several potential neu-
ropeptidergic GPCRs from the Lymnaea heart could be cloned.
Next, we used a Lymnaea brain cDNA library to isolate the
corresponding full-length clone of one of these cDNAs that was
designated GRL106.
GRL106: a novel G-protein–coupled receptor in
Lymnaea heart and brain
Primary structure comparisons suggest that the putative protein
product predicted from the GRL106 cDNA is a GPCR. This is
based on the presence of seven hydrophobic segments that could
serve as transmembrane domains, conserved amino acid residues
within these domains, as well as the Cys 171–Cys247 combination
that may form a stabilizing disulfide bridge. Like all GPCRs,
GRL106 contains N-linked glycosylation sites within the N ter-
minal and serine and threonine phosphorylation sites within
putative intracellular segments. Moreover, GRL106 seems to be
most closely related to GPCRs of the neuropeptide receptor type,
such as the Drosophila NPY receptor and vertebrate tachykinin
receptors (Shigemoto et al., 1990; Li et al., 1992). Amino acid
sequence similarity is highest in the seven transmembrane do-
mains, as is seen for all GPCRs. However, unequivocal proof that
GRL106 is a GPCR comes from expression in Xenopus oocytes in
which we show the protein to activate a G-protein–coupled
pathway after addition of LyCEP (see below).
LyCEP: a brain-derived RFamide ligand for GRL106
We set out to identify the putative neuropeptide ligand of
GRL106 using a Xenopus oocyte expression system. Because the
NPY and tachykinin receptors are known to trigger the liberation
Figure 5. Effect of LyCEP on isolated CDC neurons. A, Effect of LyCEP
on membrane potential. A representative intracellular recording of an
isolated CDC at the resting membrane potential (260 mV) to which 10
mM LyCEP (top) or vehicle (bottom) was applied under continuous super-
fusion. The horizontal line indicates the moment and duration of applica-
tion. B, Effect of LyCEP on spiking activity. A representative intracellular
recording of an isolated CDC with spontaneous beating activity to which
5 mM LyCEP (top) or vehicle (bottom) was applied under continuous
superfusion. The horizontal line indicates the moment and duration of
application.
Figure 6. LyCEP immunoreactivity in the pericard. A strongly immuno-
reactive axon bundle (arrows) runs through the pericard ( P). Inset, Oc-
casionally small branches arise from this tract (asterisk, out of focus in this
micrograph), penetrate the layer of mesothelial cells (Me; arrowhead), and
project toward the pericardial cavity (Pc), which may suggest that the
immunoreactive material is released into this cavity. A, Atrium. Scale bar:
100 mm; inset, 5 mm.
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of calcium from intracellular stores, we surmised that GRL106
might do so as well. Therefore, we took advantage of the possi-
bility to assay calcium mobilization in Xenopus oocytes by
voltage-clamp analysis of a calcium-dependent chloride channel
(Meyerhof et al., 1988).
A significant inward chloride current was observed after the
addition of a crude peptide extract from the Lymnaea brain to
GRL106-expressing oocytes (Fig. 2A). Thus, at least in the het-
erologous expression system, GRL106 indeed seems to be cou-
pled to calcium signaling, most probably by an endogenous
G-protein that triggers phospholipase C-mediated phosphoinosi-
tide hydrolysis (Meyerhof et al., 1988). Combining HPLC frac-
tionation of the peptide extract with the oocyte response as a
bioassay, we were able to purify an RFamide decapeptide that
was responsible for the activation of GRL106. The peptide acti-
vating GRL106 was designated LyCEP because of its high simi-
larity to the cardioexcitatory ACEP-1 peptide from Achatina
fulica (Fujimoto et al., 1990), and these peptides, together with
LUQIN from Aplysia (Aloyz and DesGroseillers, 1995), seem to
constitute a distinct subfamily of RFamides. Interestingly, the
C-terminal part of LyCEP (RPQGRF amide) is nearly identical
to the C-terminal part of the recently identified family of mam-
malian prolactin-releasing peptides (RPVGRF amide) (Hinuma
et al., 1998).
Different lines of evidence suggest LyCEP to be the natural
ligand for GRL106. First, synthetic LyCEP exhibits an EC50 of 8
nM in the oocyte assay. Other calcium-mobilizing GPCRs chal-
lenged with their cognate ligand in this system exhibit EC50 values
that are somewhat higher than the value observed for the LyCEP–
GRL106 combination (Kimura et al., 1992; Mahlmann et al.,
1994; van Kesteren et al., 1995). This is a strong indication that
LyCEP is, in fact, the GRL106 ligand. Second, not only have we
found that LyCEP-containing nerve fibers are present at sites of
GRL106 expression in the brain (Fig. 4) and the heart (Fig. 6) of
Lymnaea, but we have also established a modulatory action
of LyCEP on the activity of innervated brain and targeted heart
cells (Figs. 5, 7, respectively; see below).
LyCEP modulates a distinct set of identified GRL106-
expressing neurons within the Lymnaea brain
GRL106 was found to be predominantly expressed in the so-
called caudodorsal cells (CDCs; Fig. 4A). These neurons express
a small family of genes encoding related yet distinct prohormones
from which various neuropeptides can be derived that regulate
different aspects of egg laying and egg-laying behavior, among
which is the ovulation-inducing egg-laying hormone (Geraerts et
al., 1988).
As deduced from immunohistochemical staining of the Lym-
naea CNS with the anti-ACEP-1 antibody, the CDCs seem to be
contacted by LyCEP-containing nerve endings (Fig. 4C,D). Fur-
thermore, isolated CDCs respond to the LyCEP peptide by a
hyperpolarization and with disruption of the regular spiking
activity (Fig. 5). Thus, it seems likely that the LyCEP-containing
fibers are involved in inhibiting the snail’s egg-laying system.
Conversely, the neurons synthesizing LUQIN in Aplysia are
inhibited by peptides from the bag cells, the Aplysia equivalents of
the CDCs in Lymnaea (Rothman et al., 1983). If the LyCEP-
producing neurons were to be inhibited by the CDCs in a similar
manner, this suggests that the activities of the two systems are
mutually exclusive.
Figure 7. Effect of LyCEP on an isolated Lymnaea auricle.
A, Contractions of an auricle that was dissected from the
heart and placed in a displacement chamber. At the indicated
time (arrow), 1 mM LyCEP was applied directly onto the
auricle under continuous superfusion. B, Dose–response
curve of the increase in beat rate induced by synthetic LyCEP
on the isolated auricle. Each data point is the mean of at least
seven determinations. Error bars denote SEM.
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LyCEP is a cardioactive neuropeptide
Because its primary structure is so closely related to that of the
ACEP-1 peptide of Achatina (Fig. 3B), one would expect LyCEP
to exhibit cardioactive properties. Indeed, this seems to be the
case. First, in the pericardium surrounding the Lymnaea heart,
immunoreactive axon endings end blindly at the pericardial lu-
men (Fig. 6). This suggests that the immunoreactive material is
released into the pericardial cavity. The anti-ACEP-1 antibody
clearly discriminates LyCEP from other RFamides, such as
FMRFamide, as was shown by immunoblots (Fujiwarasakata and
Kobayashi, 1994; C. P. Tensen, unpublished data). Therefore, we
conclude that the staining by the anti-ACEP-1 antibody reveals
fibers that contain LyCEP. Similarly, the Aplysia heart has been
found to be innervated by the LUQ neurons producing LUQIN
(Skelton et al., 1992; Aloyz and DesGroseillers, 1995). Second,
the frequency of beating is increased when isolated auricle prep-
arations are challenged with synthetic LyCEP (Fig. 7). This effect
is similar to that of ACEP-1 on Achatina ventricles (Fujimoto et
al., 1990). Thus, LyCEP is both present and active at the Lymnaea
heart. Because LyCEP-containing fibers are seen to end blindly at
the pericardial lumen in immunohistochemical sections, the
LyCEP peptide will not function as a neurotransmitter. Rather, it
seems that LyCEP fulfills a modulatory role.
The ACEP-1 peptide was found to stimulate other muscles
than the heart, such as the penis retractor and buccal muscles
(Fujimoto et al., 1990). In addition, the LUQIN peptide of
Aplysia is synthesized by neurons that not only innervate the
heart but also the kidney, where they seem to be involved in
stimulating circular muscles that close the renal pore (Koester
and Alevizos, 1989). Whether LyCEP can also modulate other
Lymnaea muscles apart from the heart has to await further
investigations.
From the idea that GRL106 is not the FMRFamide receptor
and from the observations that FMRFamide and related
RFamides other than LyCEP do have (differential) effects on snail
heart activity and neurons (Cottrell and Davies, 1987; Payza,
1987), we expect that many more receptors for RFamide peptides
remain to be identified in Lymnaea.
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